Search Results
Nov 17, 2025, 16:23 ET Ikonopedia Expands Adoption of Risk Aware™ as Radiology Practices Prioritize Proactive Breast Cancer Risk Assessment
breast cancer risk.3 It integrates a broad set of risk-factors, including family history and genetic mutations such as BRCA, breast density, BMI, reproductive and hormonal variables, benign breast disease—and has undergone extensive validation in screening populations. "Our
More news about: Ikonopedia
Nov 12, 2025, 09:29 ET BMI Imaging Systems Showcases Advanced Digital Solutions at CLEARS 2025 Annual Training & Technology Seminar
Building on decades of work with agencies statewide, BMI helps convert complex collections—paper, microfilm, and microfiche—into searchable digital archives while preserving chain-of-custody and access controls. At this year's seminar, BMI is highlighting two core platforms that modernize access
More news about: BMI Imaging Systems, Inc.
Nov 10, 2025, 02:44 ET Camurus reports positive topline results for CAM2056, semaglutide monthly depot
pharmacokinetics, pharmacodynamics, and safety and tolerability of CAM2056 in 80 adult participants (16 in each cohort) with overweight or obesity (BMI=27 to 39.9) who were otherwise healthy. In the first part, participants were randomized 1:1:1 to weekly semaglutide and two formulations of CAM2056. The
More news about: Camurus AB
Nov 10, 2025, 02:41 ET Camurus reports positive topline results for CAM2056, semaglutide monthly depot
pharmacokinetics, pharmacodynamics, and safety and tolerability of CAM2056 in 80 adult participants (16 in each cohort) with overweight or obesity (BMI=27 to 39.9) who were otherwise healthy. In the first part, participants were randomized 1:1:1 to weekly semaglutide and two formulations of CAM2056. The
More news about: Camurus AB
Nov 09, 2025, 19:00 ET Innovent and SanegeneBio Announce Phase 1 Clinical Data for IBI3016 Presented at American Heart Association (AHA) 2025 Annual Meeting
6:2 ratio of IBI3016 dose group to placebo group). All subjects were Chinese, with a median age (range) of 37 years (24-54 years), 30% female, mean BMI of 25.2 kg/m², and baseline 24-hour ambulatory blood pressure (BP) mean of 122/74 mmHg. There were no significant differences in baseline characteristics
More news about: Innovent Biologics
Nov 06, 2025, 14:42 ET Nitinotes riceve l'approvazione del marchio CE per EndoZip™, il primo sistema di sutura completamente automatizzato per la gastroplastica restrittiva endoscopica
la terapia con GLP-1, e la chirurgia bariatrica invasiva. L'ESG si sta affermando come un'alternativa minimamente invasiva, rivolta ai pazienti obesi (BMI 30–40 kg/m²) che non hanno ottenuto risultati con misure conservative quali dieta, esercizio fisico o farmaci. Automatizzando
More news about: Nitinotes
Nov 06, 2025, 14:30 ET Novo Nordisk's CagriSema was associated with significant reduction in blood pressure and showed anti-inflammatory effects while reducing the proportion of patients at risk of developing heart disease over time in new analyses at ObesityWeek®
semaglutide 2.4 mg), cagrilintide 2.4 mg monotherapy and semaglutide 2.4 mg monotherapy versus placebo in 3,417 adults with obesity (BMI ≥30 kg/m2), or overweight (BMI ≥27 kg/m2) with one or more obesity-related comorbidities, and without type 2 diabetes.4
More news about: NOVO NORDISK INC.
Nov 06, 2025, 14:30 ET Novo Nordisk's CagriSema was associated with significant reduction in blood pressure and showed anti-inflammatory effects while reducing the proportion of patients at risk of developing heart disease over time in new analyses at ObesityWeek®
semaglutide 2.4 mg), cagrilintide 2.4 mg monotherapy and semaglutide 2.4 mg monotherapy versus placebo in 3,417 adults with obesity (BMI ≥30 kg/m2), or overweight (BMI ≥27 kg/m2) with one or more obesity-related comorbidities, and without type 2 diabetes.4
More news about: NOVO NORDISK INC.
Nov 06, 2025, 09:30 ET Nitinotes Receives CE Mark Approval of EndoZip™, the First Fully Automated Suturing System for Endoscopic Sleeve Gastroplasty
GLP-1 therapy and invasive bariatric surgery. ESG is emerging as a minimally invasive alternative, addressing patients with obesity (BMI 30–40 kg/m²) who have not achieved success with conservative measures such as diet, exercise, or medication. By automating suturing,
More news about: Nitinotes
Nov 06, 2025, 09:30 ET Nitinotes Receives CE Mark Approval of EndoZip™, the First Fully Automated Suturing System for Endoscopic Sleeve Gastroplasty
management such as GLP-1 therapy and invasive bariatric surgery. ESG is emerging as a minimally invasive alternative, addressing patients with obesity (BMI 30–40 kg/m²) who have not achieved success with conservative measures such as diet, exercise, or medication. By automating suturing,
More news about: Nitinotes
Nov 06, 2025, 07:04 ET Mwyngil Therapeutics Announces In-Licensing of GPR75 Modulators and Cell-Surface Discovery Platform from Expert Systems Inc.
liver, kidney, and vascular endothelium. Human genetic studies have linked loss-of-function variants of GPR75 with lower body-mass index (BMI), enhanced insulin sensitivity, and protection from obesity and type 2 diabetes (T2D). GPR75 reverse agonists, which
More news about: Mwyngil Therapeutics
Nov 06, 2025, 00:54 ET METRO BRANDS UNVEILS METROACTIV: INDIA'S NEXT CHAPTER IN ATHLETIC FOOTWEAR RETAIL
aesthetics with local engagement. The e-commerce platform complements this experience with wellness tools such as a Calorie Counter, Nutrition Tracker, and BMI Calculator, enabling users to track, shop, and stay active within a single connected ecosystem. Pan India operations linked seamlessly to physical stores
More news about: Metro Brands Limited
Nov 05, 2025, 08:15 ET Novo Nordisk presents four new analyses on oral semaglutide 25 mg (Wegovy® in a pill*) at ObesityWeek® 2025, including demonstrated reductions in cardiovascular risk factors
placebo-controlled trial evaluating the efficacy and safety of once-daily oral semaglutide 25 mg versus placebo in 307 adults with obesity (BMI ≥ 30 kg/m2) or overweight (BMI ≥ 27 kg/m2) with one or more weight-related comorbidities.5 People with diabetes were excluded.5
More news about: NOVO NORDISK INC.
Nov 05, 2025, 08:15 ET Novo Nordisk presents four new analyses on oral semaglutide 25 mg (Wegovy® in a pill*) at ObesityWeek® 2025, including demonstrated reductions in cardiovascular risk factors
placebo-controlled trial evaluating the efficacy and safety of once-daily oral semaglutide 25 mg versus placebo in 307 adults with obesity (BMI ≥ 30 kg/m2) or overweight (BMI ≥ 27 kg/m2) with one or more weight-related comorbidities.5 People with diabetes were excluded.5
More news about: NOVO NORDISK INC.
Nov 04, 2025, 16:01 ET MetaVia to Present New Phase 1 and Pre-Clinical Data on DA-1726 at ObesityWeek® 2025
tolerability, PK, and pharmacodynamics (PD) of single and multiple ascending doses of DA-1726 in obese but otherwise healthy adults with a body mass index (BMI) of 30–45 kg/m². Each of the 4 cohorts presented in the poster included nine participants randomized 6:3 to receive four once-weekly subcutaneous doses
More news about: MetaVia Inc.
Nov 04, 2025, 12:04 ET Currax Announces ObesityWeek® Data Showing that CONTRAVE® Helps Curb Cravings and Offers Marked Effectiveness in Certain Populations with Obesity
reduced-calorie diet and increased physical activity for chronic weight management in adults with an initial body mass index (BMI) of 30 kg/m2 or greater (obese), or adults with a BMI of 27 kg/m2 or greater (overweight) with at least one weight-related medical problem such as high blood pressure,
More news about: Currax Pharmaceuticals LLC
Nov 04, 2025, 12:00 ET RO TO PRESENT EIGHT RESEARCH ABSTRACTS AT OBESITYWEEK 2025
Patients with class IV obesity (BMI>50 kg/m²) face substantial health risks, but in-person care may be less desirable to these patients due to physical limitations and weight bias. This study examined the demographic and clinical characteristics of patients with BMI > 50 kg/m² seeking treatment
More news about: Ro
Nov 04, 2025, 10:30 ET Bariatric Beds Market to Reach $583.8 million, Globally, by 2034 at 5.3% CAGR: Allied Market Research
largely driven by the increasing global prevalence of obesity and obesity-related health conditions. As more individuals qualify as morbidly obese (with a BMI ≥ 40), healthcare providers are investing in specialized equipment that ensures safety, comfort, and effective treatment for this patient's population.
More news about: Allied Market Research
Nov 04, 2025, 08:00 ET Lipocine Presents LPCN 2401 Clinical Data at ObesityWeek®
In this Phase 2 trial, men with BMI ≥27 kg/m2 with metabolic dysfunction associated steatohepatitis were randomized (1:1:1) to one of three treatments:1) LPCN 2401, 2) LPCN 2401
More news about: Lipocine Inc.
Nov 03, 2025, 03:47 ET 諾和諾德於香港推出體重管理藥物維秀美® （Wegovy®）
體重指數 BMI ≥ 30 kg/m²的成人，或 體重指數BMI ≥27 至 <30 kg/m²的成人並伴隨至少一項體重相關疾病，如高血糖（糖尿病前期或二型糖尿病）、高血壓、血脂異常、阻塞性睡眠窒息、心血管疾病等，或 12歲及以上患有肥胖症的青少年（體重指數 BMI ≥ 95百分位，依據美國疾病管制與預防中心所制定的性別與年齡特定體重指數圖表），且體重超過
More news about: 諾和諾德
Oct 30, 2025, 12:41 ET Currax Pharmaceuticals to Spotlight New Research at ObesityWeek® 2025 Highlighting Craving Control, Behavioral Adherence, and Subpopulation Outcomes with CONTRAVE®
reduced-calorie diet and increased physical activity for chronic weight management in adults with an initial body mass index (BMI) of 30 kg/m2 or greater (obese), or adults with a BMI of 27 kg/m2 or greater (overweight) with at least one weight-related medical problem such as high blood pressure,
More news about: Currax Pharmaceuticals LLC
Oct 29, 2025, 12:43 ET Currax Pharmaceuticals to Spotlight New Research at ObesityWeek® 2025 Highlighting Craving Control, Behavioral Adherence, and Subpopulation Outcomes with CONTRAVE®
reduced-calorie diet and increased physical activity for chronic weight management in adults with an initial body mass index (BMI) of 30 kg/m2 or greater (obese), or adults with a BMI of 27 kg/m2 or greater (overweight) with at least one weight-related medical problem such as high blood pressure,
More news about: Currax Pharmaceuticals LLC
Oct 26, 2025, 20:00 ET Innovent's Mazdutide Shows Superiority in Glycemic Control with Weight Loss over Semaglutide in a Head-to-head Phase 3 Clinical Trial DREAMS-3
activity for chronic weight management in adult patients with an initial Body Mass Index (BMI) of: BMI ≥ 28 kg/m² (obesity); or BMI ≥ 24 kg/m² (overweight) in the presence of at least one weight-related comorbid condition
More news about: Innovent Biologics
Oct 23, 2025, 09:02 ET Currax Pharmaceuticals LLC to Provide CONTRAVE® at No Cost to Federal Employees During Government Shutdown
CONTRAVE?CONTRAVE is a prescription weight-loss medicine that may help some adults with a body mass index (BMI) of 30 kg/m2 or greater (obese), or adults with a BMI of 27 kg/m2 or greater (overweight) with at least one weight-related medical problem such as high blood pressure,
More news about: Currax Pharmaceuticals LLC
Oct 23, 2025, 08:55 ET Oramed Releases Letter to Shareholders, Highlighting Developments in its Oral Insulin Program, Significant Investment Appreciation, and Upcoming Growth Initiatives
data, we identified high-responder subgroups that demonstrated particularly encouraging results. These subgroups, including participants with lower BMI and older demographics, showed the possibility of achieving over 1% reduction in HbA1c, a clinically meaningful outcome that potentially strengthens
More news about: Oramed Pharmaceuticals Inc.